Rare cardiomyopathy

Rare cardiomyopathy (Orphanet code 167848) is a broad grouping term used in the Orphanet classification to encompass uncommon forms of cardiomyopathy that do not fall neatly into the major categories of hypertrophic, dilated, restrictive, or arrhythmogenic right ventricular cardiomyopathy. Cardiomyopathies are diseases of the heart muscle (myocardium) that impair the heart's ability to pump blood effectively throughout the body. Under this umbrella, various rare subtypes exist, including left ventricular noncompaction cardiomyopathy, endocardial fibroelastosis, and other unclassified or mixed-phenotype cardiomyopathies. The cardiovascular system is primarily affected, though secondary effects on the pulmonary, hepatic, and renal systems may occur due to heart failure. Key clinical features vary depending on the specific subtype but commonly include progressive heart failure symptoms such as dyspnea (shortness of breath), fatigue, exercise intolerance, palpitations, peripheral edema, and syncope (fainting). Some forms carry an increased risk of arrhythmias and sudden cardiac death. Onset can range from the neonatal period to adulthood depending on the underlying etiology, which may be genetic, acquired, or idiopathic. Many genetic forms follow autosomal dominant inheritance, though autosomal recessive, X-linked, and mitochondrial patterns are also observed across different subtypes. Treatment is largely supportive and symptom-directed, as no curative therapy exists for most rare cardiomyopathies. Standard heart failure management includes medications such as ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists. Implantable cardioverter-defibrillators (ICDs) may be indicated for patients at high risk of sudden cardiac death, and cardiac resynchronization therapy can be considered in selected cases. Heart transplantation remains an option for patients with end-stage disease refractory to medical therapy. Genetic counseling is recommended for familial forms, and ongoing research into gene therapy and targeted molecular treatments offers hope for future disease-modifying interventions.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Rare cardiomyopathy